KHKirk J. Hogan

Kirk J. Hogan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kirk J. Hogan has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Reid S. Alisch

    Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison, USA

    7 shared publications
  • Andy Madrid

    Department of Neurological Surgery University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

    4 shared publications
  • Ligia A. Papale

    Department of Neurological Surgery University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

    4 shared publications
  • Sterling C. Johnson

    Wisconsin Alzheimer’s Disease Research Center, School of Medicine and Public Health, University of Wisconsin, Madison, USA

    4 shared publications
  • Lindsay R. Clark

    Geriatric Research Education and Clinical Center William S. Middleton Memorial Veterans Hospital Madison Wisconsin USA

    3 shared publications
  • Lindsay R. Clark

    University of Wisconsin‐Madison School of Medicine and Public Health, Madison, WI, USA

    3 shared publications

Latest Publications

  • Open Access

    Differential DNA methylation in blood in nuclear genes that encode mitochondrial proteins in mild cognitive impairment and Alzheimer’s disease

    by Alexander E. Boruch, Andy Madrid, Ligia A. Papale, Phillip E. Bergmann, Isabelle Renteria, Samuel Faasen, Dane B. Cook, Reid S. Alisch, Kirk J. Hogan

    Background: Altered mitochondrial function contributes to the pathogenesis of mild cognitive impairment (MCI) and late-onset dementia due to Alzheimer’s disease (AD). Objective: To test for differential methylation in nuclear genes that encode proteins that participate in mitochondrial function between cognitively unimpaired participants (CU) and those with MCI and AD. Methods: Recently published whole genome methylation sequencing (WGMS) in blood from CU participants ( N =174), and those with MCI ( N =99) and AD ( N =109) was used to test for differential methylation in 1,121 nuclear genes that encode proteins that participate in mitochondrial function in the Human Protein Atlas . Results: Seventy-four nuclear genes that encode proteins that participate in mitochondrial function were differentially methylated between persons with MCI and CU. Seventy-one genes were differentially methylated between persons with AD and CU, and 132 genes were differentially methylated between persons with MCI and AD. Thirteen differentially methylated genes shared between the 3 comparisons support contributions from disrupted metabolism and oxidative stress pathways in AD pathogenesis. Conclusions: Nuclear genes that encode proteins that participate in mitochondrial glucose metabolism, fatty acid metabolism and oxidative stress pathways are differentially methylated between persons who are CU and those with MCI and AD.


  • Open Access

    Sex-Specific Differential DNA Methylation in Mild Cognitive Impairment and Alzheimer’s Disease

    by Phillip E. Bergmann, Andy Madrid, Ligia A. Papale, Lindsay R. Clark, Sanjay Asthana, Sterling C. Johnson, Sündüz Keleş, Kirk J. Hogan, Reid S. Alisch

    Sex differences in late-onset Alzheimer’s disease (AD) progression include accelerated decrements in cognitive status and greater amyloid and tau biomarker burdens in females. To identify sex-specific differentially methylated positions (DMPs) and genes in persons with mild cognitive impairment (MCI) and AD, we analyzed whole genome methylation sequencing on blood samples from participants with MCI (N=99, 52% female), AD (N=109, 43% female), and those cognitively unimpaired (CU; N=174, 52% female). Ninety-four percent of DMPs from MCI vs . CU, AD vs . CU, and AD vs . MCI pairwise comparisons were sex-specific. Female-specific DMPs were enriched in neurologic gene sets ( e.g ., synaptic membrane, ion channel complex), while male-specific DMPs showed limited enrichment. Sex-specific DMPs overlapped blood-specific enhancers, promoters, and transcription factor binding motifs, highlighting divergent epigenetic regulation by sex. These findings identify sex-specific genes and molecular pathways in MCI and AD and support that blood DNA methylation levels can distinguish cognitive status.


  • Open Access

    Whole genome methylation sequencing in blood from persons with mild cognitive impairment and dementia due to Alzheimer's disease identifies cognitive status

    by Andy Madrid, Ligia A. Papale, Phillip E. Bergmann, Coleman Breen, Lindsay R. Clark, Sanjay Asthana, Sterling C. Johnson, Sündüz Keleş, Kirk J. Hogan, Reid S. Alisch

    INTRODUCTION: Whole genome methylation sequencing (WGMS) in blood identifies differential DNA methylation in persons with late‐onset dementia due to Alzheimer's disease (AD) but has not been tested in persons with mild cognitive impairment (MCI). METHODS: We used WGMS to compare DNA methylation levels at 25,244,219 CpG loci in 382 blood samples from 99 persons with MCI, 109 with AD, and 174 who are cognitively unimpaired (CU). RESULTS: WGMS identified 9756 differentially methylated positions (DMPs) in persons with MCI, including 1743 differentially methylated genes encoding proteins in biological pathways related to synapse organization, dendrite development, and ion transport. A total of 447 DMPs exhibit progressively increasing or decreasing DNA methylation levels among CU, MCI, and AD that correspond to cognitive status. DISCUSSION: WGMS identifies DMPs in known and newly detected genes in blood from persons with MCI and AD that support blood DNA methylation levels can distinguish cognitive status. Highlights: Whole genome methylation levels in blood from 99 persons with mild cognitive impairment (MCI), 109 with Alzheimer's disease, and 174 who are cognitively unimpaired were analyzed. Nine thousand seven hundred fifty‐six differentially methylated positions (DMPs) were identified in MCI. One thousand seven hundred forty‐three genes comprise one or more DMPs in persons with MCI. Fifty‐eight DMPs and 392 differentially methylated genes are shared among the three pairwise comparisons. Four hundred forty‐seven DMPs exhibit progressive changes that correspond to cognitive status.


  • Open Access

    Whole genome methylation sequencing in blood from persons with mild cognitive impairment and dementia due to Alzheimer’s disease identifies cognitive status

    by Andy Madrid, Ligia A. Papale, Phillip E. Bergmann, Coleman Breen, Lindsay R. Clark, Sanjay Asthana, Sterling C. Johnson, Sündüz Keleş, Kirk J. Hogan, Reid S. Alisch

    INTRODUCTION Whole genome methylation sequencing (WGMS) in blood identifies differential DNA methylation in persons with late-onset dementia due to Alzheimer’s disease (AD) but has not been tested in persons with mild cognitive impairment (MCI). METHODS We used WGMS to compare DNA methylation levels at 25,244,219 CpG loci in 382 blood samples from 99 persons with MCI, 109 with AD, and 174 who are cognitively unimpaired (CU). RESULTS WGMS identified 9,756 differentially methylated positions (DMPs) in persons with MCI, including 1,743 differentially methylated genes encoding proteins in biological pathways related to synapse organization, dendrite development, and ion transport. 447 DMPs exhibit progressively increasing or decreasing DNA methylation levels between CU, MCI, and AD that correspond to cognitive status. DISCUSSION WGMS identifies DMPs in known and newly detected genes in blood from persons with MCI and AD that support blood DNA methylation levels as candidate biomarkers of cognitive status.


  • Open Access

    Whole genome methylation sequencing in blood identifies extensive differential DNA methylation in late‐onset dementia due to Alzheimer's disease

    by Coleman Breen, Ligia A. Papale, Lindsay R. Clark, Phillip E. Bergmann, Andy Madrid, Sanjay Asthana, Sterling C. Johnson, Sündüz Keleş, Reid S. Alisch, Kirk J. Hogan

    INTRODUCTION: DNA microarray‐based studies report differentially methylated positions (DMPs) in blood between late‐onset dementia due to Alzheimer's disease (AD) and cognitively unimpaired individuals, but interrogate < 4% of the genome.METHODS: We used whole genome methylation sequencing (WGMS) to quantify DNA methylation levels at 25,409,826 CpG loci in 281 blood samples from 108 AD and 173 cognitively unimpaired individuals.RESULTS: WGMS identified 28,038 DMPs throughout the human methylome, including 2707 differentially methylated genes (e.g., SORCS3, GABA, and PICALM) encoding proteins in biological pathways relevant to AD such as synaptic membrane, cation channel complex, and glutamatergic synapse. One hundred seventy‐three differentially methylated blood‐specific enhancers interact with the promoters of 95 genes that are differentially expressed in blood from persons with and without AD.DISCUSSION: WGMS identifies differentially methylated CpGs in known and newly detected genes and enhancers in blood from persons with and without AD.Highlights: Whole genome DNA methylation levels were quantified in blood from persons with and without Alzheimer's disease (AD). Twenty‐eight thousand thirty‐eight differentially methylated positions (DMPs) were identified. Two thousand seven hundred seven genes comprise DMPs. Forty‐eight of 75 independent genetic risk loci for AD have DMPs. One thousand five hundred sixty‐eight blood‐specific enhancers comprise DMPs, 173 of which interact with the promoters of 95 genes that are differentially expressed in blood from persons with and without AD.


  • Molecular Genetic Diagnosis of Human Malignant Hyperthermia

    by Kirk Hogan

    A point mutation in the skeletal muscle calcium release channel, which is also called the ryanodine receptor or RYR1, was first found to be co-inherited with a predisposition to malignant hyperthermia (MH) in the pig. 1 The gene encoding the RYR1 protein is one of the largest and most complex known, consisting of over 250,000 nucleotide bases with more than 100 boundaries between coding (exon) and noncoding (intron) regions. 2 The search for a mutation in a gene this large was warranted by a substantial body of genetic3–6 and biochemical 7 – 11 evidence pointing to a disorder of the RYR1 in pig MH. The discovery of the cytosine to thymine substitution at nucleotide 1843 was made by comparing the DNA sequences of the normal and mutant RYR1 alleles. The mutation, producing a cysteine for arginine substitution at position 615 of the RYR1 amino acid sequence (R615C), subsequently has been identified in over 450 pigs derived from six breeding strains, and thus far all pig MH can be traced to this alteration (Chapter 18).

  • DNA methylation and hydroxymethylation have distinct genome-wide profiles related to axonal regeneration

    by Andy Madrid, Laura E. Borth, Kirk J. Hogan, Nithya Hariharan, Ligia A. Papale, Reid S. Alisch, Bermans J. Iskandar

    Alterations in environmentally sensitive epigenetic mechanisms (e.g., DNA methylation) influence axonal regeneration in the spinal cord following sharp injury. Conventional DNA methylation detection methods using sodium bisulphite treatment do not distinguish between methylated and hydroxymethylated forms of cytosine, meaning that past studies report a composite of 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). To identify the distinct contributions of DNA methylation modifications to axonal regeneration, we collected spinal cord tissue after sharp injury from untreated adult F3 male rats with enhanced regeneration of injured spinal axons or controls, derived from folate- or water-treated F0 lineages, respectively. Genomic DNA was profiled for genome-wide 5hmC levels, revealing 658 differentially hydroxymethylated regions (DhMRs). Genomic profiling with whole genome bisulphite sequencing disclosed regeneration-related alterations in composite 5mC + 5hmC DNA methylation levels at 2,260 differentially methylated regions (DMRs). While pathway analyses revealed that differentially hydroxymethylated and methylated genes are linked to biologically relevant axon developmental pathways, only 22 genes harbour both DhMR and DMRs. Since these differential modifications were more than 60 kilobases on average away from each other, the large majority of differential hydroxymethylated and methylated regions are unique with distinct functions in the axonal regeneration phenotype. These data highlight the importance of distinguishing independent contributions of 5mC and 5hmC levels in the central nervous system, and denote discrete roles for DNA methylation modifications in spinal cord injury and regeneration in the context of transgenerational inheritance.


  • Open Access

    Correction to: Ancestral Folate Promotes Neuronal Regeneration in Serial Generations of Progeny

    by Nirav J. Patel, Kirk J. Hogan, Elias Rizk, Krista Stewart, Andy Madrid, Sivan Vadakkadath Meethal, Reid Alisch, Laura Borth, Ligia A. Papale, Solomon Ondoma, et al.

    The original version of this article unfortunately contained error in Figure 4a to where some of the text was overlapping.

  • DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimer’s Disease

    by Andy Madrid, Kirk J. Hogan, Ligia A. Papale, Lindsay R. Clark, Sanjay Asthana, Sterling C. Johnson, Reid S. Alisch

    Differentially methylated positions (DMPs) between persons with and without late-onset Alzheimer’s disease (LOAD) were observed at 477 of 769,190 loci in a plurality of genes. Of these, 17 were shared with DMPs identified using clinical LOAD markers analyzed independently as continuous variables comprising Rey Auditory Verbal Learning Test scores, cerebrospinal fluid total tau (t-tau) and phosphorylated tau 181 (p-tau 181 ) levels, and t-tau/Aβ1–42 (Aβ 42 ), p-tau 181 /Aβ 42 , and Aβ 42 /Aβ1–40 (Aβ 40 ) ratios. In patients with LOAD, 12 of the shared 17 DMPs were hypomethylated in B3GALT4 (Beta-1,3-galatcosyltransferase 4) (EC 2.4.1.62), and 5 were hypomethylated in ZADH2 (Prostaglandin reductase 3) (EC 1.3.1.48).